Washington, DC - A secondary analysis of the Hemodialysis (HEMO) Study highlights the significant biases in trial results that can occur when as-treated vs intention-to-treat methodology is applied [ ...
The most comprehensive, randomized clinical trial of hemodialysis therapy to-date has confirmed the adequacy of current dosage guidelines. The researchers also found that using high-flux filters to ...
Study: At-home hemodialysis more effective than peritoneal dialysis as more options come to the fore
Peritoneal dialysis is the most common kind of at-home dialysis, given its relative convenience and ease of use compared to hemodialysis. But now, in the largest study of its kind, a massive 5-year ...
Please provide your email address to receive an email when new articles are posted on . Average annual injectable drug expenditures for in-center hemodialysis were $20,000. Total annual costs were ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Patient-Centered Outcomes Research Institute (PCORI ...
Researchers receive PCORI funding to study the effectiveness of individualized model of hemodialysis
The Patient-Centered Outcomes Research Institute (PCORI) recently awarded researchers at Wake Forest University School of Medicine $10.2 million to study the effectiveness of an individualized model ...
For hemodialysis patients, undergoing dialysis for eight hours overnight, three times weekly, reduces the risk of death by nearly 80 percent, compared to conventional, four-hour dialysis, according to ...
A new study reveals that hemodialysis may reduce blood flow to the brain in older patients being treated for kidney failure. The findings, which appear in an upcoming issue of the Journal of the ...
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx ...
One-third of older patients with end-stage kidney disease received an arteriovenous fistula within 6 months of starting ...
TORONTO, March 24, 2026--(BUSINESS WIRE)--The first patient has been treated in a unique clinical trial to evaluate the safety and efficacy of a novel pharmacologic intervention aimed at preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results